Rodon Biologics

Executive Summary

Rodon Biologics is a Portuguese contract research and manufacturing organization (CRO/CDMO) specializing in recombinant protein and antibody services. Founded in 2018, the company leverages over two decades of team experience to provide end-to-end solutions, including protein engineering, cell line development, analytical characterization, formulation, and GMP-compliant manufacturing. With expertise in both microbial fermentation and mammalian cell culture, Rodon supports clients from discovery through clinical development. Positioned in Lisbon, Portugal, the company benefits from a competitive cost structure and access to European biotech hubs. As the biologics market expands, Rodon is well-placed to capture growing outsourced demand, particularly for pre-clinical and early-stage projects. Its private status and lack of disclosed financials suggest a focus on steady operational growth, but the company's comprehensive service portfolio and experienced team provide a solid foundation for capturing market share in the European CRO/CDMO landscape.

Upcoming Catalysts (preview)

• Q3 2027Expansion of GMP Manufacturing Capacity70% success
• Q4 2026Strategic Partnership with Major Biopharma50% success
• Q1 2027ISO 13485 Certification for Quality Management90% success